Hims & Hers Health Class Action Lawsuit Alert: Upcoming Deadline for Lead Plaintiff Motion

Strategic Insights -

Investors who suffered losses on their Hims & Hers Health, Inc. ("Hims") investments may be eligible to join a class action lawsuit. The lawsuit alleges that Hims made false and misleading statements about its business and prospects, particularly regarding its collaboration with Novo Nordisk. On April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, which included the sale of Novo Nordisk's FDA-approved Wegovy on the Hims & Hers platform. However, on June 23, 2025, Novo Nordisk issued a press release announcing the termination of its partnership with Hims due to the company's deceptive promotion and sale of illegitimate, knockoff versions of Wegovy. As a result, Hims' share price fell by 34.6% on June 23, 2025. The class action lawsuit alleges that Hims failed to disclose material adverse facts about its business and operations, including its deceptive promotion and sale of illegitimate versions of Wegovy.

Key Takeaways:

  • The class action lawsuit alleges that Hims made false and misleading statements about its business and prospects, particularly regarding its collaboration with Novo Nordisk.
  • Hims' share price fell by 34.6% on June 23, 2025, after Novo Nordisk announced the termination of its partnership due to Hims' deceptive practices.
  • The lawsuit alleges that Hims failed to disclose material adverse facts about its business and operations, including its sale of illegitimate versions of Wegovy.
  • The deadline for lead plaintiff motion in the class action lawsuit is August 25, 2025.
  • Investors who purchased or otherwise acquired Hims securities between April 29, 2025 and June 23, 2025 may be eligible to join the lawsuit.
  • The lawsuit alleges that Hims engaged in deceptive practices, including the promotion and sale of illegitimate versions of Wegovy.

Statistics:

  • Hims' share price fell by $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025.
  • The lawsuit alleges that Hims failed to disclose material adverse facts about its business and operations, including its sale of illegitimate versions of Wegovy.
  • The deadline for lead plaintiff motion is August 25, 2025.
  • Investors who purchased or otherwise acquired Hims securities between April 29, 2025 and June 23, 2025 may be eligible to join the lawsuit.

Sources:

  • GlobeNewswire, "Hims & Hers Health, Inc. Class Action Lawsuit Reminder"
  • Glancy Prongay & Murray LLP, "Hims & Hers Health, Inc. Class Action Lawsuit"